Published in Cell Cycle on May 01, 2011
Short telomeres in ESCs lead to unstable differentiation. Cell Stem Cell (2013) 1.61
Reduced Oct4 expression directs a robust pluripotent state with distinct signaling activity and increased enhancer occupancy by Oct4 and Nanog. Cell Stem Cell (2013) 1.42
JNK and STAT3 signaling pathways converge on Akt-mediated phosphorylation of EZH2 in bronchial epithelial cells induced by arsenic. Cell Cycle (2012) 1.06
Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther (2013) 1.06
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells. Exp Mol Pathol (2012) 1.01
Concise review: pursuing self-renewal and pluripotency with the stem cell factor Nanog. Stem Cells (2013) 1.00
Regulation of breast cancer stem cell features. Contemp Oncol (Pozn) (2015) 0.97
The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model. Exp Mol Pathol (2011) 0.96
The polycomb protein Ezh2 impacts on induced pluripotent stem cell generation. Stem Cells Dev (2014) 0.89
Probing the role of stochasticity in a model of the embryonic stem cell: heterogeneous gene expression and reprogramming efficiency. BMC Syst Biol (2012) 0.86
Epigenetic events in liver cancer resulting from alcoholic liver disease. Alcohol Res (2013) 0.81
E2f6-mediated repression of the meiotic Stag3 and Smc1β genes during early embryonic development requires Ezh2 and not the de novo methyltransferase Dnmt3b. Epigenetics (2013) 0.79
Epigenetic Nanog regulation and the role of functional heterogeneity. Cell Cycle (2011) 0.78
Significance of epigenetic landscape in cartilage regeneration from the cartilage development and pathology perspective. Stem Cells Dev (2014) 0.78
A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma. PLoS One (2014) 0.78
Current status in cancer cell reprogramming and its clinical implications. J Cancer Res Clin Oncol (2016) 0.77
Transcriptomic Profiling and H3K27me3 Distribution Reveal Both Demethylase-Dependent and Independent Regulation of Developmental Gene Transcription in Cell Differentiation. PLoS One (2015) 0.77
Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics (2016) 0.77
"Super p53" mice display retinal astroglial changes. PLoS One (2013) 0.77
Uropathogenic E.coli (UPEC) Infection Induces Proliferation through Enhancer of Zeste Homologue 2 (EZH2). PLoS One (2016) 0.76
An Ezh way to turn off Nanog. Cell Cycle (2011) 0.76
Establishment of a proteome profile and identification of molecular markers for mouse spermatogonial stem cells. J Cell Mol Med (2014) 0.75
Digital quantitation of HCC-associated stem cell markers and protein quality control factors using tissue arrays of human liver sections. Exp Mol Pathol (2014) 0.75
Nono, a Bivalent Domain Factor, Regulates Erk Signaling and Mouse Embryonic Stem Cell Pluripotency. Cell Rep (2016) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc (2008) 62.52
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Nanog safeguards pluripotency and mediates germline development. Nature (2007) 13.01
Chromatin signatures of pluripotent cell lines. Nat Cell Biol (2006) 12.88
Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics (2005) 10.64
The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol (2007) 8.57
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Nanog is the gateway to the pluripotent ground state. Cell (2009) 7.27
The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol (2001) 7.20
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell (2008) 6.86
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat Immunol (2002) 5.67
Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J (1997) 5.25
Capturing pluripotency. Cell (2008) 5.08
Early lineage segregation between epiblast and primitive endoderm in mouse blastocysts through the Grb2-MAPK pathway. Dev Cell (2006) 4.77
Regulated fluctuations in nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol (2009) 4.60
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A (2005) 4.57
The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol (2005) 4.52
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
A genome-wide RNAi screen identifies a new transcriptional module required for self-renewal. Genes Dev (2009) 4.23
A heterogeneous expression pattern for Nanog in embryonic stem cells. Stem Cells (2007) 4.04
Polycomb repressive complex 2 is dispensable for maintenance of embryonic stem cell pluripotency. Stem Cells (2008) 3.81
A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci (2003) 3.26
The transcriptional foundation of pluripotency. Development (2009) 3.21
H3K27 demethylases, at long last. Cell (2007) 3.02
Withdrawal of differentiation inhibitory activity/leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells. Oncogene (1996) 2.83
Satb1 and Satb2 regulate embryonic stem cell differentiation and Nanog expression. Genes Dev (2009) 1.67
Regulation of stem cell differentiation by histone methyltransferases and demethylases. Cold Spring Harb Symp Quant Biol (2008) 1.22
Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation. Development (2010) 1.15
The hallmarks of aging. Cell (2013) 14.29
Tumour biology: senescence in premalignant tumours. Nature (2005) 10.15
Cellular senescence in cancer and aging. Cell (2007) 9.04
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature (2009) 7.39
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A (2008) 5.21
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev (2007) 5.07
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol (2009) 4.51
The common biology of cancer and ageing. Nature (2007) 4.28
"Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J (2002) 4.17
Delayed ageing through damage protection by the Arf/p53 pathway. Nature (2007) 3.87
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell (2009) 3.36
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun (2010) 2.97
Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell (2008) 2.85
The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer (2006) 2.85
Programmed cell senescence during mammalian embryonic development. Cell (2013) 2.78
Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen. Emerg Infect Dis (2002) 2.76
The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell (2004) 2.65
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell (2011) 2.56
Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature (2006) 2.51
The stress kinase MKK7 couples oncogenic stress to p53 stability and tumor suppression. Nat Genet (2011) 2.47
Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature (2013) 2.47
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 2.43
Depletion of ribosomal protein L37 occurs in response to DNA damage and activates p53 through the L11/MDM2 pathway. Cell Cycle (2010) 2.41
Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One (2009) 2.30
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis (2004) 2.29
p53: guardian of the genome and policeman of the oncogenes. Cell Cycle (2007) 2.23
A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (2011) 2.13
SIRT1: recent lessons from mouse models. Nat Rev Cancer (2010) 2.07
Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci U S A (2006) 1.98
Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res (2007) 1.97
miR-33-mediated downregulation of p53 controls hematopoietic stem cell self-renewal. Cell Cycle (2010) 1.95
The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res (2009) 1.87
Tumour biology: Policing of oncogene activity by p53. Nature (2006) 1.86
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab (2012) 1.81
Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. Genes Dev (2004) 1.71
IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney Int (2012) 1.59
Raf-1 regulates Rho signaling and cell migration. J Cell Biol (2005) 1.58
Nephrin deficiency activates NF-kappaB and promotes glomerular injury. J Am Soc Nephrol (2009) 1.57
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55
Usefulness of plasma cardiotrophin-1 in assessment of left ventricular hypertrophy regression in hypertensive patients. J Hypertens (2005) 1.53
Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int (2014) 1.52
A mammalian microRNA cluster controls DNA methylation and telomere recombination via Rbl2-dependent regulation of DNA methyltransferases. Nat Struct Mol Biol (2008) 1.51
Time course of changes in collateral blood flow and isolated vessel size and gene expression after femoral artery occlusion in rats. Am J Physiol Heart Circ Physiol (2004) 1.50
Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle (2008) 1.50
Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci U S A (2010) 1.48
Polycomb mediated epigenetic silencing and replication timing at the INK4a/ARF locus during senescence. PLoS One (2009) 1.48
SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol (2010) 1.48
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun (2007) 1.40
WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res (2009) 1.39
Critique of hyperglycemia and surgical site infection. J Trauma Acute Care Surg (2014) 1.38
Re: Tibial Stress Fracture Secondary to Half-pins in Circular Ring External Fixation for Charcot Foot. Foot Ankle Int (2014) 1.38
The Arf/p53 pathway in cancer and aging. Cancer Res (2008) 1.37
Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep (2005) 1.36
Genome-wide CTCF distribution in vertebrates defines equivalent sites that aid the identification of disease-associated genes. Nat Struct Mol Biol (2011) 1.31
Increased p53 activity does not accelerate telomere-driven ageing. EMBO Rep (2006) 1.30
Essential role of B-Raf in ERK activation during extraembryonic development. Proc Natl Acad Sci U S A (2006) 1.28
Whole genome analysis of p38 SAPK-mediated gene expression upon stress. BMC Genomics (2010) 1.25
Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J (2008) 1.25
ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle (2006) 1.24
Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep (2003) 1.24
p27(Kip1) directly represses Sox2 during embryonic stem cell differentiation. Cell Stem Cell (2012) 1.23
Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression. PLoS One (2009) 1.22
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
PTEN in cancer, metabolism, and aging. Trends Endocrinol Metab (2012) 1.18
p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol (2010) 1.18
The absence of p53 is critical for the induction of apoptosis by 5-aza-2'-deoxycytidine. Oncogene (2004) 1.18
Resistance to viral infection of super p53 mice. Oncogene (2005) 1.17
Dietary restriction: standing up for sirtuins. Science (2010) 1.17
Contrast-enhanced whole-heart coronary MRA at 3.0T for the evaluation of cardiac venous anatomy. Int J Cardiovasc Imaging (2010) 1.17
Activation of cyclin D1-kinase in murine fibroblasts lacking both p21(Cip1) and p27(Kip1). Oncogene (2002) 1.15
Thermosensitive injectable hyaluronic acid hydrogel for adipose tissue engineering. Biomaterials (2009) 1.15
Impact of Sirt1 on mammalian aging. Aging (Albany NY) (2010) 1.13
Expanding metabolism for total biosynthesis of the nonnatural amino acid L-homoalanine. Proc Natl Acad Sci U S A (2010) 1.13
Antibiotic resistance amongst healthcare-associated pathogens in China. Int J Antimicrob Agents (2012) 1.13
Anti-aging activity of the Ink4/Arf locus. Aging Cell (2009) 1.13
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation provides a biomarker for the action of exisulind and related agents that activate protein kinase G. Mol Cancer Ther (2002) 1.12
Cellular senescence limits regenerative capacity and allograft survival. J Am Soc Nephrol (2012) 1.11
A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques. Clin Vaccine Immunol (2012) 1.10
EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep (2012) 1.10
The senescent side of tumor suppression. Cell Cycle (2005) 1.08
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax. J Infect Dis (2011) 1.08
Celecoxib-induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G. Mol Carcinog (2008) 1.08
Crosstalk between PKCzeta and the IL4/Stat6 pathway during T-cell-mediated hepatitis. EMBO J (2004) 1.07
In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. PLoS One (2012) 1.06
Dissecting the role of mTOR complexes in cellular senescence. Cell Cycle (2012) 1.05
VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats. Am J Physiol Heart Circ Physiol (2004) 1.05